Jazz Pharmaceuticals PLC at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Fantastic. All right. So I guess maybe one of the pertinent questions we received, probably closer to April, right, when this all sort of began with new patient diagnosis, right, within the sleep franchise, right? Now we've all sort of adapted. And I think a lot of people have sort of got to probably a level of comfort that I'd imagine that going to a sleep center, one is comfortable it's not a hospital. So how should we think about, obviously, the challenges that persist with new patient diagnosis within sleep, yet maybe some of the misconceptions that now, as we go forward and as COVID drags on that you and Jazz have sought to address?

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Great. And maybe just staying on sleep before moving to Zepzelca, but I think something that, again, we've discussed a lot with investors and obviously, you've got tremendous amount of questions about this is the switch from Xyrem to Xywav or how that will happen. Will you switch patients? And I think a lot of the thinking has been that it won't be a hard switch, it will probably be data driven over time. And I think you put out a press release -- I believe it was this week, I apologize if it was last week, but about your collaboration with the American Heart Association. Now I think that with the backdrop of a lower sodium product, I think, was a very interesting collaboration and a very important collaboration. Can you just talk a little bit more about that collaboration?

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Great. Thank you very much. Maybe just moving on to Zepzelca. I think it's fantastic to hear that, that product is off to a good start because I think it is really something that is truly needed for these -- for that patient population. I think it can make a big difference for them. You mentioned perhaps looking at first-line or other tumor types. Can you just remind us what your current agreement with PharmaMar contemplates in terms of what you have licensed versus what we may see licensed in the future?

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Great. And I agree with you there. Maybe just staying on Zepzelca quickly. We do have top line data from ATLANTIS coming out. This was not designed as a confirmatory trial. However, I think a lot of people are looking at it from the investment community as potentially being a confirmatory REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 16, 2020 / 5:20PM, JAZZ.OQ - Jazz Pharmaceuticals PLC at Cantor Fitzgerald Global Healthcare Conference (Virtual) trial. So when we do see the data, I think there a few things, I think, the investment community, are going to look at, but I think the prescribing community may not look at it in the same way, right, versus looking at how this is performing in practice, quality of life from their patients. So maybe what is your feel -- and maybe it's too early, but from the prescribing community about the ATLANTIS data, why do you think this is purely a regulatory and Wall Street focus right now?

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Great. We've got about 2 minutes left, but I do want to try and squeeze in two more. So quickly on JZP-458. Obviously, manufacturing has been a challenge for your partner there. Should 458 get approved, how quickly do you think you could scale up manufacturing to meet the demand that is out there and we wouldn't have shortages?

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Beg your pardon, Bruce. Yes.

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Great. And lastly, just on business development. Obviously, this is a question you've received for a number of years. And I think what has shown up in this space, at least for the last 5, 10 years, is that discipline and not overpaying is a much better strategy in the longer term. So maybe could you just talk about how you see valuations currently in the current environment of assets and companies that may fit into? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 16, 2020 / 5:20PM, JAZZ.OQ - Jazz Pharmaceuticals PLC at Cantor Fitzgerald Global Healthcare Conference (Virtual)

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Great. Thank you very much, Bruce. We are out of time. I'd love to continue this discussion just given how much you've achieved this year and how much lies ahead, but thank you very much for joining us today. That does end the session.